Screening platform to identify therapeutic drugs or agents for treatment of alzheimer's disease
A technology for therapeutic agents and substances, which is applied in the field of screening platforms for identifying therapeutic drugs or reagents for the treatment of Alzheimer's disease, and can solve problems such as unclear CD33 activity
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment
[0118] overview
[0119] As indicated, compounds were selected and tested in microglia and 3D AD cell culture models at a range of concentrations and over time periods ranging from hours to days. Culture models were chosen to elucidate the different stages and biological aspects of Alzheimer's disease. Using a commercially available assay that measures LDH release (CytoTox-ONE TM , Promega) assay media to assess compound toxicity. Toxic concentrations were excluded from further testing. For microglial cultures, Aβ42 and Aβ40 uptake assays were performed for 2 to 24 hours after 3 hours of compound pretreatment. Alternatively, LPS-activation assays were performed for 3 hours after 3 hours of compound pretreatment. The reduction of toxic cytokines released in the culture medium was monitored.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


